Open an account

HUTCHMED (China)

HCM · HONG

$14.36+$0.08 (+0.56%)TodayMarket closed ·
Prev close $14.28

About HCM

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Employees
1,796
Headquarters
Hong Kong
Listed
May 19, 2006
Sector
Health Care
Industry
Pharmaceuticals
Website
hutch-med.com

HCM key statistics

Market cap
20.17B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
52.76K
Volume
23.39K
Open price
$14.36
High today
$14.80
Low today
$14.26
52 Week high
$16.33
52 Week low
$9.77

HUTCHMED (China) (HCM) at a glance

As of Oct 23, 2026, HUTCHMED (China) (HCM) shares are priced at $14.36, giving the company a market cap of 20.17B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $14.26 and $14.80. The current price is 0.7% above the day's low and 3.0% below its high.

Volume so far is 23.39K shares, below the average of 52.76K shares a day.

Over the past year HUTCHMED (China) has ranged from $9.77 to $16.33, and now sits 70% of the way up that range.

HUTCHMED (China) met or beat analyst EPS estimates in 5 of the last 5 quarters. In Q2 FY23 it reported $0.19 per share against an estimate of -$0.3811.

The average analyst price target is $19.94, 38.9% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 15 analystsAvg $19.94
Low
$12.23
Now
$14.36
High
$28.18

HCM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 5 quarters, by 93.9% on average.

  1. Q2 FY20: reported -$0.07 per share against an estimate of -$0.5459
  2. Q4 FY20: reported -$0.11 per share against an estimate of -$0.4429
  3. Q2 FY21: reported -$0.14 per share against an estimate of -$0.7725
  4. Q4 FY21: reported -$0.259 per share against an estimate of -$1.06
  5. Q2 FY23: reported $0.19 per share against an estimate of -$0.3811

HCM news

  • Vandana Singh

    Why Is HUTCHMED Stock Soaring Thursday?

  • Vandana Singh

    AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories

  • Vandana Singh

    AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies

  • Vandana Singh

    HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial

  • An Overview of HUTCHMED (China)'s Earnings

  • Vandana Singh

    Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

  • Press releasePRNewswire

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

  • Avi Kapoor

    Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday

Similar companies

Companies in the same industry as HUTCHMED (China)

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.